|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
US6291161B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
|
HU215180B
(hu)
|
1992-01-23 |
1998-10-28 |
Merck Patent Gmbh. |
Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
|
|
CZ206195A3
(en)
|
1993-02-12 |
1996-04-17 |
Univ Leland Stanford Junior |
Controlled transcription of target genes and other biological materials
|
|
US6972193B1
(en)
|
1993-02-12 |
2005-12-06 |
Board Of Trustees Of Leland Stanford Junior University |
Regulated transcription of targeted genes and other biological events
|
|
ES2229236T3
(es)
|
1994-01-11 |
2005-04-16 |
Dyax Corporation |
Inhibidores de la plasmina humana derivados de los dominios de kunitz.
|
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
|
CA2318402A1
(en)
|
1998-01-15 |
1999-07-22 |
Ariad Gene Therapeutics, Inc. |
Regulation of biological events using multimeric chimeric proteins
|
|
AU766513B2
(en)
|
1998-02-13 |
2003-10-16 |
Board Of Trustees Of The Leland Stanford Junior University |
Novel dimerizing agents, their production and use
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
CN103555733A
(zh)
|
2005-01-05 |
2014-02-05 |
F-星生物技术研究与开发有限公司 |
分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
|
|
GB0504767D0
(en)
|
2005-03-08 |
2005-04-13 |
Ares Trading Sa |
Lipocalin protein
|
|
EP1829895A1
(en)
|
2006-03-03 |
2007-09-05 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
|
|
WO2010062966A2
(en)
|
2008-11-26 |
2010-06-03 |
The General Hospital Corporation |
Methods for inducing mixed chimerism
|
|
WO2011146862A1
(en)
|
2010-05-21 |
2011-11-24 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing selective apoptosis
|
|
ES2791716T3
(es)
|
2010-12-14 |
2020-11-05 |
Univ Maryland |
Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer
|
|
EP3470431A1
(en)
|
2012-09-27 |
2019-04-17 |
Merus N.V. |
Bispecific igg antibodies as t cell engagers
|
|
EP4303232A3
(en)
|
2013-02-15 |
2024-04-17 |
The Regents of The University of California |
Chimeric antigen receptor and methods of use thereof
|
|
EP2964253A1
(en)
|
2013-03-05 |
2016-01-13 |
Baylor College Of Medicine |
Heparanase expression in human t lymphocytes
|
|
WO2015017214A1
(en)
|
2013-07-29 |
2015-02-05 |
Bluebird Bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
US10287354B2
(en)
*
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
US20170081411A1
(en)
*
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
EP3288974B1
(en)
|
2015-05-01 |
2020-11-04 |
Inhibrx, Inc. |
Type iii secretion system targeting molecules
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP3341410B1
(en)
|
2015-08-24 |
2021-06-02 |
Cellectis |
Chimeric antigen receptors with integrated controllable functions
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
WO2017180993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
AU2018385699B2
(en)
|
2017-12-14 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Daric interleukin receptors
|
|
JP7060084B2
(ja)
|
2018-03-26 |
2022-04-26 |
三菱マテリアル株式会社 |
絶縁回路基板用接合体の製造方法および絶縁回路基板用接合体
|
|
US12097219B2
(en)
|
2018-09-10 |
2024-09-24 |
Legend Biotech Ireland Limited |
Single-domain antibodies against CLL1 and constructs thereof
|
|
CA3121478A1
(en)
|
2018-11-30 |
2020-06-04 |
Aleta Biotherapeutics Inc. |
Single domain antibodies against cll-1
|
|
AU2019397152A1
(en)
|
2018-12-14 |
2021-06-24 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020123938A1
(en)
|
2018-12-14 |
2020-06-18 |
Bluebird Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US20240034768A1
(en)
|
2018-12-14 |
2024-02-01 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US12291560B2
(en)
|
2018-12-14 |
2025-05-06 |
Regeneron Pharmaceuticals, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
KR20220004751A
(ko)
|
2019-05-04 |
2022-01-11 |
인히브릭스, 인크. |
CLEC12a 결합 폴리펩타이드 및 이의 용도
|
|
CA3139512A1
(en)
|
2019-05-08 |
2020-11-12 |
Inhibrx, Inc. |
Cd123 targeted immunotherapies
|
|
US12421315B2
(en)
|
2019-05-08 |
2025-09-23 |
Regeneron Pharmaceuticals, Inc. |
CLL-1 targeted immunotherapies
|
|
AU2020359530A1
(en)
|
2019-09-30 |
2022-05-19 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2021207613A1
(en)
|
2020-04-10 |
2021-10-14 |
2Seventy Bio, Inc. |
Frb antibodies
|
|
CA3225252A1
(en)
|
2021-07-14 |
2023-01-19 |
Jordan JARJOUR |
Engineered t cell receptors fused to binding domains from antibodies
|